市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Biomea Fusion, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.9
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.88 |
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 9.76% |
| 机构持股比例 | 45.04% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 18.00 (HC Wainwright & Co., 984.34%) | 购买 |
| 中 | 16.00 (863.86%) | |
| 低 | 7.00 (Piper Sandler, 321.69%) | 购买 |
| 平均值 | 13.67 (723.49%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 2.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 24 Jun 2025 | 16.00 (863.86%) | 购买 | 1.88 |
| 18 Jun 2025 | 16.00 (863.86%) | 购买 | 1.91 | |
| Piper Sandler | 03 Jun 2025 | 7.00 (321.69%) | 购买 | 2.49 |
| HC Wainwright & Co. | 06 May 2025 | 18.00 (984.34%) | 购买 | 1.67 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合